Our 2024 Partner
United Immunity
Expertise Partner
United Immunity is developing a Myeloid Targeting Platform™ comprising of Cholesteryl Pullulan (CHP) based nanogels and lipid nanoparticles to target therapeutic payloads (small molecules, mRNA, etc.) to macrophages and dendritic cells for the treatment of cancer, fibrosis, infectious, autoimmune, and inflammatory diseases. UI-102 applies CHP to precisely deliver a TLR7/8 agonist to tumor-associated macrophages and change refractory cold tumors into hot tumors. United's platform is also being applied to T-cell booster vaccines and in vivo CAR-macrophages.